The CTLA-4 inhibitors pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
LAS VEGAS, May 31, 2023 /PRNewswire/ -- DelveInsight's 'CTLA-4 Inhibitors Competitive Landscape - 2023' report provides comprehensive global coverage of available, marketed, and pipeline CTLA-4 inhibitors in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the CTLA-4 inhibitors competitive domain.
Key Takeaways from the CTLA-4 Inhibitors Competitive Landscape Report
- Over 40+ CTLA-4 inhibitors companies are evaluating 50+ CTLA-4 inhibitors drugs in various stages of development, and their anticipated acceptance in the CTLA-4 inhibitors market would significantly increase market revenue.
- Key CTLA-4 inhibitors companies such as Innovent Biologics, Alphamab Oncology, Agenus, Harbour BioMed, AstraZeneca, Alpine Immune Sciences, Henlix Biotech, DotBio, TrueBinding, Ocean Biomedical, Xencor, Molecular Templates, Akeso, Inc., TRACON Pharmaceuticals, Inc., Biocytogen Pharmaceuticals, and others are evaluating new CTLA-4 inhibitors drugs to improve the treatment landscape.
- Promising CTLA-4 inhibitors pipeline drugs such as KN046, IBI-310, Botensilimab, Porustobart, Tremelimumab, Davoceticept, HLX-13, DB-002, IMT-400, OCX 909, Vudalimab, MT-8421, AK104, YH001, and others are under different phases of CTLA-4 inhibitors clinical trials.
- In March 2023, Molecular Templates, Inc. received clearance from the United States Food and Drug Administration ("FDA") following a review of its Investigational New Drug Application ("IND") to proceed with clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors. Preclinical data from MT-8421 showed that in a transgenic mouse model expressing human CTLA-4 and bearing syngeneic subcutaneous tumors, MT-8421 treatment depleted immune suppressive Tregs in the TME but not in the periphery.
- In October 2022, the FDA approved the CTLA-4 immune checkpoint inhibitor tremelimumab (Imjudo) as part of a first-line immunotherapy combination for unresectable hepatocellular cancer (HCC). Under the specifics of the new indication, tremelimumab is given as a single 300 mg priming dose along with the PD-L1 inhibitor durvalumab (Imfinzi) at a dose of 1,500 mg every 4 weeks -- dubbed the STRIDE regimen (single tremelimumab, regular interval durvalumab).
- In August 2022, Biocytogen Pharmaceuticals and TRACON Pharmaceuticals, Inc., jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of Phase I/II clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy.
- In June 2022, Akeso, Inc. announced that its PD-1/CTLA-4 bi-specific antibody (Cadonilimab injection, AK104) has received marketing approval from the National Medical Products Administration (NMPA) of China, for the treatment of relapsed or metastatic cervical cancer (R/M CC) patients who progressed on or after platinum-based chemotherapy.
- In November 2022, Xencor, Inc. announced the presentation of data from the first patients in the Phase 2 combination study of vudalimab, a selective PD-1 x CTLA-4 XmAb® bispecific antibody, in patients with metastatic castration-resistant prostate cancer (mCRPC) and data from multiple preclinical-stage XmAb programs at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston. A patient in Cohort E with an 89% reduction in PSA from baseline experienced a partial response (PR) at week 18 and continued treatment at 35 weeks. Treatment continued for one additional patient in Cohort C, at 4 weeks. In addition to the patient experiencing a PR in Cohort E, six other patients were efficacy evaluable and experienced the best response of stable disease (n=5) or non-complete response/non-progressive disease (non-CR/non-PD; n=1).
Request a sample and discover the recent advances in CTLA-4 inhibitors @ CTLA-4 Inhibitors Competitive Landscape Report
CTLA-4 Inhibitors Overview
CTLA-4 (cytotoxic T lymphocyte antigen-4) is a key negative regulator of T cell activation. The well-defined B7:CD28/CTLA-4 pathway controls the production and maintenance of immune responses through a complex integration of positive and negative co-stimulatory signals. Inhibiting negative regulation via CTLA-4 binding has been demonstrated to increase adaptive immunity stimulation and T cell activation potentiation. CTLA-4-blocking antibodies have shown efficacy as monotherapy in several murine malignancy models; additionally, they have shown synergistic anti-tumor action when combined with other treatments such as vaccinations, chemotherapy, and radiation.
T cell activation necessitates not only stimulation of the T cell receptor (TCR) on antigen-presenting cells (APCs) by peptide-major histocompatibility complexes (MHCs) but also an orchestrated balance of co-stimulatory and inhibitory signals that modulate the magnitude and effectiveness of the immune response. Multiple mechanisms control the activation of effector CD4+ and CD8+ T lymphocytes (Teffs), including cell surface proteins that augment or suppress T cell responses. Negative regulatory proteins on T cells, including CTLA-4, PD-1, B7 family member B7-H4, T cell immunoglobulin and mucin domain-containing protein 3 (Tim-3), and lymphocyte activation gene-3 (LAG-3), interact with their cognate ligands on a variety of cell types, including APCs, regulatory T cells (Tregs), and nonhematopoietic cells, resulting in decreased T cell proliferation and functional activity.
Find out more about CTLA-4 inhibitors drugs @ CTLA-4 Inhibitors Analysis
CTLA-4 Inhibitors Pipeline Analysis: Drug Profile
KN046: Alphamab Oncology
Jiangsu Alphamab developed KN046 as an independent PD-L1/CTLA-4 bispecific antibody. Its new designs include: a CTLA-4 domain combined with a PD-L1 single-domain antibody; tailored to target the tumor microenvironment with high PD-L1 expression; and Treg inhibits tumor immunity-clearing activity. In Australia and China, there are over 20 clinical trials using KN046 in various phases covering more than ten types of tumors including NSCLC, thymic cancer, pancreatic cancer, HCC, ESCC, and TNBC. The outcomes of these clinical trials have revealed good data in terms of patient survival. Based on the clinical outcomes in China and Australia, Alphamab Oncology has acquired FDA approval to begin later-stage trials of KN046. Furthermore, KN046 has been granted orphan drug status by the US Food and medication administration for thymic epithelial tumor in September 2020. Four key clinical trials are presently underway. The drug is currently in Phase III development for the treatment of Squamous Non-small-cell Lung Cancer.
IBI-310: Innovent Biologics
IBI-310 is under development for the treatment of advanced, recurrent, or metastatic non-small-cell lung cancer(NSCLC), unresectable or relapsed or metastatic advanced Biliary tract cancer, metastatic solid tumors including advanced hepatocellular carcinoma, recurrent and metastatic nasopharyngeal carcinoma, acral melanoma, liver cancer, cervical cancer, renal cell carcinoma, EBV-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The medication candidate is delivered intravenously. It works by interacting with the cytotoxic T-lymphocyte protein 4 receptor (CTLA4). It was also being studied as a therapy for metastatic melanoma and metastatic colorectal adenocarcinoma. The medication is currently under Phase III clinical trial evaluation for the treatment of Hepatocellular Carcinoma.
A snapshot of the CTLA-4 Inhibitors Pipeline Drugs mentioned in the report:
CTLA-4 Inhibitors Drugs | Company | Phase | Indication |
KN046 | Alphamab Oncology | Phase III | Non-small cell lung cancer; Pancreatic cancer |
IBI-310 | Innovent Biologics | Phase III | Acral lentiginous melanoma; Liver cancer |
Cadonilimab | Akeso Biopharma | Phase III | Gastric cancer; Liver cancer; Oesophageal cancer |
Tremelimumab | AstraZeneca | Phase III | Bladder cancer; Head and neck cancer; Mesothelioma; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Urogenital cancer |
Botensilimab | Agenus | Phase II | Colorectal cancer; Malignant melanoma; Pancreatic cancer; Solid tumors |
Porustobart | Harbour BioMed | Phase II | Liver cancer; Neuroendocrine tumors; Renal cell carcinoma; Solid tumors |
Vudalimab | Xencor | Phase II | Biliary cancer; Gynecological cancer; Prostate cancer; Urogenital cancer |
Davoceticept | Alpine Immune Sciences | Phase I | Lymphoma; Solid tumors |
OCX 909 | Elkurt/Ocean Biomedical/Ocean Chitorx | Preclinical | Glioblastoma |
MT-8421 | Molecular Templates | Preclinical | Solid Tumors |
Learn more about the emerging CTLA-4 inhibitors pipeline drugs @ CTLA-4 Inhibitors Clinical Trials
Scope of the CTLA-4 Inhibitors Competitive Landscape Report
- Coverage: Global
- Key CTLA-4 Inhibitors Companies: Innovent Biologics, Alphamab Oncology, Agenus, Harbour BioMed, AstraZeneca, Alpine Immune Sciences, Henlix Biotech, DotBio, TrueBinding, Ocean Biomedical, Xencor, Molecular Templates, Akeso, Inc., TRACON Pharmaceuticals, Inc., Biocytogen Pharmaceuticals, and others
- Key CTLA-4 Inhibitors Pipeline Drugs: KN046, IBI-310, Botensilimab, Porustobart, Tremelimumab, Davoceticept, HLX-13, DB-002, IMT-400, OCX 909, Vudalimab, MT-8421, AK104, YH001, and others
- Company Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive drugs assessment, Unmet Needs
Dive deep into rich insights for new CTLA-4 inhibitors drugs, visit @ CTLA-4 Inhibitors Drugs
Table of Contents
1. | CTLA-4 Inhibitors Pipeline Report Introduction |
2. | CTLA-4 Inhibitors Pipeline Report Executive Summary |
3. | CTLA-4 Inhibitors Pipeline: Overview |
4. | CTLA-4 Inhibitors Marketed Drugs |
4.1. | Yervoy: Bristol Myers Squibb |
5. | CTLA-4 Inhibitors Clinical Trial Therapeutics |
6. | CTLA-4 Inhibitors Pipeline: Late-Stage Products (Pre-registration) |
7. | CTLA-4 Inhibitors Pipeline: Late-Stage Products (Phase III) |
7.1. | KN046: Alphamab Oncology |
8. | CTLA-4 Inhibitors Pipeline: Mid-Stage Products (Phase II) |
8.1. | Botensilimab: Agenus |
9. | CTLA-4 Inhibitors Pipeline: Early-Stage Products (Phase I) |
10. | CTLA-4 Inhibitors Pipeline Therapeutics Assessment |
11. | Inactive Products in the CTLA-4 Inhibitors Pipeline |
12. | Company-University Collaborations (Licensing/Partnering) Analysis |
13. | Unmet Needs |
14. | CTLA-4 Inhibitors Market Drivers and Barriers |
15. | Appendix |
For further information on the CTLA-4 inhibitors pipeline therapeutics, reach out @ CTLA-4 Inhibitors Therapeutic Assessment
Related Reports
PD-1 Inhibitor Pipeline
PD-1 Inhibitor Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitor companies, including Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., among others.
PD-1 and PD-L1 Inhibitors Competitive Landscape
PD-1 and PD-L1 Inhibitors Competitive Landscape - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, among others.
JAK Inhibitors Competitive Landscape
JAK Inhibitors Competitive Landscape - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.
TIGIT Inhibitors Competitive Landscape
TIGIT Inhibitors Competitive Landscape - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ctla-4-inhibitors-clinical-trial-pipeline-delveinsight-highlights-major-advances-transformative-therapies-and-40-leading-players-wheeling-the-therapeutics-segment-301838119.html
